Zurcher Kantonalbank Zurich Cantonalbank Has $256,000 Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 20.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 56,706 shares of the biotechnology company’s stock after buying an additional 9,767 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in ADMA Biologics were worth $256,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the stock. Cambridge Investment Research Advisors Inc. raised its holdings in shares of ADMA Biologics by 31.3% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 15,000 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 3,572 shares in the last quarter. Sawgrass Asset Management LLC purchased a new stake in shares of ADMA Biologics during the 3rd quarter worth about $55,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of ADMA Biologics during the 3rd quarter valued at about $58,000. Commonwealth Equity Services LLC grew its stake in shares of ADMA Biologics by 61.8% in the 3rd quarter. Commonwealth Equity Services LLC now owns 16,360 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 6,250 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in ADMA Biologics in the third quarter worth approximately $65,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Insider Transactions at ADMA Biologics

In related news, Director Steve Elms sold 49,887 shares of the business’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $6.01, for a total transaction of $299,820.87. Following the transaction, the director now owns 2,527,500 shares of the company’s stock, valued at $15,190,275. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last quarter, insiders have sold 639,895 shares of company stock worth $3,927,169. Insiders own 3.70% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on ADMA. HC Wainwright reiterated a “buy” rating and issued a $7.50 target price (up from $6.00) on shares of ADMA Biologics in a research note on Tuesday, March 26th. Cantor Fitzgerald lifted their price objective on shares of ADMA Biologics from $6.50 to $8.00 and gave the company an “overweight” rating in a research note on Thursday, February 29th. Finally, Mizuho upped their price objective on shares of ADMA Biologics from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, March 1st. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $7.88.

ADMA Biologics Stock Performance

Shares of ADMA opened at $6.91 on Tuesday. The company has a market capitalization of $1.58 billion, a PE ratio of -53.15 and a beta of 0.43. The company has a debt-to-equity ratio of 1.04, a current ratio of 5.16 and a quick ratio of 1.69. ADMA Biologics, Inc. has a one year low of $3.06 and a one year high of $6.94. The company’s fifty day moving average price is $6.24 and its 200 day moving average price is $5.04.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.02. The business had revenue of $73.90 million during the quarter, compared to analysts’ expectations of $73.50 million. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. As a group, analysts expect that ADMA Biologics, Inc. will post 0.3 earnings per share for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.